Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Asset Writedowns and Impairment: 2019-2025

Historic Asset Writedowns and Impairment for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $7,000.

  • Biodesix's Asset Writedowns and Impairment was N/A to $7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $209,000, marking a year-over-year change of. This contributed to the annual value of $238,000 for FY2024, which is 19.00% up from last year.
  • As of Q3 2025, Biodesix's Asset Writedowns and Impairment stood at $7,000, which was down 73.08% from $26,000 recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Asset Writedowns and Impairment peaked at $400,000 during Q1 2022, and registered a low of -$267,000 during Q4 2023.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $70,500 (2024), whereas its average is $54,400.
  • Per our database at Business Quant, Biodesix's Asset Writedowns and Impairment soared by 6,533.33% in 2021 and then crashed by 486.96% in 2023.
  • Quarterly analysis of 5 years shows Biodesix's Asset Writedowns and Impairment stood at $193,000 in 2021, then soared by 107.25% to $69,000 in 2022, then slumped by 486.96% to -$267,000 in 2023, then spiked by 138.58% to $103,000 in 2024, then slumped by 61.19% to $7,000 in 2025.
  • Its Asset Writedowns and Impairment was $7,000 in Q3 2025, compared to $26,000 in Q2 2025 and $73,000 in Q1 2025.